Loading
Life sciences · Journal article
Indian Journal of Nuclear Medicine · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Testicular metastasis from prostate carcinoma is exceedingly rare and generally indicates advanced disease with a poor prognosis. We report the case of a 61-year-old man with metastatic prostate carcinoma who developed progressive disease despite chemotherapy, androgen deprivation therapy, and androgen receptor pathway inhibitor therapy. Dual-tracer imaging with 68 Ga prostate-specific membrane antigen (PSMA)-11 positron emission tomography/computed tomography (PET/CT) and 18 F Fluorodeoxyglucose (FDG) PET/CT was performed before planned lutetium 177 PSMA radioligand therapy ( 177 Lu- PSMA RLT). [ 68 Ga]Ga-PSMA PET/CT demonstrated tracer-avid lesions in the prostate, bone, lymph nodes, and right testis, whereas the testicular lesion was non-avid on 18 F-FDG PET/CT, demonstrating a discordant uptake pattern similar to that of other metastatic sites. Clinical examination revealed a firm, painless right scrotal mass. Based on the serial imaging findings and clinical context, testicular metastasis was diagnosed without biopsy. This case highlights the value of combined [ 68 Ga]Ga-PSMA and 18 F-FDG PET/CT in detecting and characterising rare metastatic sites noninvasively with increased diagnostic confidence.